Patents Assigned to Merck
  • Cyanopyrimidine derivatives
    Patent number: 11261163
    Abstract: The present invention relates to compounds of formula M in which RM has the meaning indicated in claim 1, to liquid crystal mixture comprising the same, to the use of these liquid-crystal media, in particular in components for high-frequency technology, and to components of this type which contain media according to the invention, and to the production and use of these components. The components according to the invention are suitable, in particular, as phase shifters in the microwave and millimetre wave region, for microwave and millimetre wave array antennae and very particularly for so-called tunable “reflectarrays”.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: March 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Matthias Bremer, Atsutaka Manabe
  • Bicyclic heterocyclic derivatives
    Patent number: 11261185
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: March 1, 2022
    Assignee: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Materials for electronic devices
    Patent number: 11261291
    Abstract: The present application relates to a polymer containing at least one structural unit of a formula (I) and at least one further structural unit selected from structural units A, B and C. The present application further relates to the use of the polymer in an electronic device and to a process for preparing the polymer. The present application further relates to an electronic device comprising the polymer.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 1, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Beate Burkhart, Katja Maria Scheible, Nils Koenen, Holger Heil
  • BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
    Publication number: 20220056017
    Abstract: The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Jinsong HAO, Shishi LIN, Michael T. RUDD, Lan WEI, Li XIAO, Dexi YANG
  • GLAZING COMPRISING A SWITCHABLE DEVICE, LAMINATED STRUCTURE AND METHOD FOR MANUFACTURING OF A GLAZING
    Publication number: 20220055351
    Abstract: A glazing (10) comprising a switchable optical device (26) is proposed. The switchable optical device (26) has a layer structure comprising in this order a first substrate (12), a switchable layer (18) and a second substrate (24). Further, at least one of the first substrate (12) and the second substrate (24) is attached to a further sheet (30) by means of an adhesive tape (40) or an optically clear adhesive (48). Further aspects of the invention relate to a laminated structure and an insulated glazing unit comprising such a glazing (10) and a method for manufacturing of such a glazing (10).
    Type: Application
    Filed: December 17, 2019
    Publication date: February 24, 2022
    Applicant: Merck Patent GmbH
    Inventors: Rainer NEEFF, Michael JUNGE
  • SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING
    Publication number: 20220056045
    Abstract: The instant invention is related to a novel solid form of ceftolozane sulfate (the DMAc solvate of ceftolozane sulfate (Form 3)), compositions comprising ceftolozane sulfate DMAc solvate (Form 3), synthesis of Form 3 and an improved crystallization process using Form 3 to prepare ceftolozane sulfate Form 2. Novel compositions also include ceftolozane sulfate solid Form 3 and/or other crystalline and amorphous solid forms of ceftolozane.
    Type: Application
    Filed: June 1, 2017
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin Matthew Maloney, Eric M. Sirota, Richard J. Varsolona, Donald R. Gauthier, Jr., Hong Ren
  • NOVEL CRYSTALLINE FORMS OF AN NRTTI COMPOUND
    Publication number: 20220056067
    Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.
    Type: Application
    Filed: December 16, 2019
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daniel Skomski, Yongchao Su, Wei Xu, Marko Cubrovic
  • TREATING INFECTIONS WITH CEFTOLOZANE/TAZOBACTAM IN SUBJECTS HAVING IMPAIRED RENAL FUNCTION
    Publication number: 20220054460
    Abstract: Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
    Type: Application
    Filed: February 2, 2021
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gopal KRISHNA, Gurudatt A. CHANDORKAR, Elham HERSHBERGER, Benjamin MILLER, Alan XIAO
  • POLYMERIZABLE LIQUID CRYSTAL INK FORMULATIONS
    Publication number: 20220056340
    Abstract: The present invention relates to polymerizable liquid crystalline formulations and especially to an ink formulation for inkjet printing comprising 10 to 50% w/w of one or more polymerizable liquid crystalline compounds and 50 to 90% w/w of one or more organic solvents selected from the group of aliphatic ketones, cyclic ketones, alkyl ethers of ethylene glycol or propylene glycol, alkyl esters of menthyl or aromatic solvents.
    Type: Application
    Filed: December 9, 2019
    Publication date: February 24, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Eduardo Beltran GRACIA, Stephen MULCAHY, Daniel WALKER
  • ARGINASE INHIBITORS AND METHODS OF USE
    Publication number: 20220056051
    Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
    Type: Application
    Filed: December 13, 2019
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Symon Gathiaka, Charles A. Lesburg, Derun Li, Min Lu, Matthew J. Mitcheltree, Anandan Palani, Rachel L. Palte, Hongjun Zhang
  • Compounds and organic electronic devices
    Patent number: 11258018
    Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. The present invention furthermore relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: February 22, 2022
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro, Amir Parham, Arne Buesing, Frank Voges
  • Crosslinking p-dopants for p-doping organic hole conductors
    Patent number: 11258020
    Abstract: A method produces cross-linked hole-conducting electric layers by converting functionalized p-dopants. The functionalized p-dopants are organic metal complexes containing at least one central atom and organic ligands, wherein the central atom is selected from a metal of the groups 6-15 of the periodic table, and at least one of the organic ligands is selected from the following formulas I-V, in which E independently of one another is oxygen, sulfur, selenium, or N(E1)x, and each Rv has at least one functionalizing group selected from the group RF including —OH, —COOH, —NH2, —NHR?, halogen, C2-C40-alkenyl, -dienyl, -alkinyl, -alkenyloxy, -dienyloxy, -alkinyloxy, acrylic acid, oxetan, oxiran, silane, acrylic acid, anhydride, and cyclobutane or consists of the groups, and G=C(RF)uHvFw where u+v+w=3 and n=1-4.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: February 22, 2022
    Assignees: OSRAM OLED GmbH, MERCK Patent GmbH
    Inventors: Günter Schmid, Florian Kessler, Katja Stegmaier, Fabrice Eckes, Holger Heil, Beate Burkhart, Henning Seim
  • Liquid-crystalline medium and high-frequency components comprising same
    Patent number: 11254874
    Abstract: The present invention relates to liquid-crystalline media comprising one or more chiral compounds and one or more compounds selected from the group of compounds of formulae I, II and III, in which the parameters have the meaning indicated in claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 22, 2022
    Assignee: Merck Patent GmbH
    Inventors: Michael Wittek, Dagmar Klass
  • Liquid crystal media comprising polymerisable compounds
    Patent number: 11254872
    Abstract: Liquid crystal (LC) media comprising polymerisable compounds as further specified in the description and claims and a self-alignment additive for vertical alignment. The media are adapted for use in LC displays, especially in LC displays of the polymer-sustained alignment type.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: February 22, 2022
    Assignee: Merck Patent GmbH
    Inventors: Helmut Haensel, Steffen Gnauck, Qiong Tong, Sabrina Zeiss
  • Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
    Patent number: 11246929
    Abstract: Combination therapy for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: February 15, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Damstrup, Thomas Grombacher, Christian Sirrenberg, Lyubomir Vassilev, Astrid Zimmermann
  • Particle size and distribution of polymer for melt extrusion application
    Patent number: 11246935
    Abstract: An extrudable polyvinyl alcohol (PVA) powder with improved flowability containing particles of PVA, which has been cryo-milled, and which has d50 particle sizes in the range of 45 to 1400 ?m; or which has a particle size distribution of d10=20±10 ?m, d20=30±10 ?m, d50=70±10 ?m, d90=200±30 ?m, and d99=300±30 ?m; and a powdery composition for the preparation of pharmaceutical formulations which contains the polyvinyl alcohol homogeneously mixed with at least one active pharmaceutical ingredient (API); and a process for producing a solid pharmaceutical dosage form by extruding or forming a homogeneous melt of a mixture of ingredients containing the powdered polyvinyl alcohol and at least one active pharmaceutical ingredient (API), and forming a powder or a molded form.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: February 15, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Lubda, Mengyao Zheng, Nicole Di Gallo, Anja-Nadine Knuettel
  • Polymerisable LC medium and polymer film with flat optical dispersion
    Patent number: 11248171
    Abstract: The invention relates to a polymerisable LC medium with flat optical dispersion, a polymer film with flat optical dispersion obtainable from such a medium, and the use of the polymerisable LC medium and polymer film in optical, electro optical, electronic, semiconducting or luminescent components or devices.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 15, 2022
    Assignee: Merck Patent GmbH
    Inventors: Eduardo Beltran Gracia, Iain Gardiner, Rebecca Proctor, Stephen Mulcahy
  • Method for producing fluorinated compounds
    Patent number: 11247960
    Abstract: The present invention relates to a process for the preparation of fluorinated compounds, to novel compounds containing fluorinated end groups, to the use thereof and to compositions comprising novel compounds containing fluorinated end groups.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: February 15, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Reiner Friedrich, Fabian Koch
  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20220041727
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 10, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PROCESS FOR THE PREPARATION OF A COATED SOLID PHARMACEUTICAL DOSAGE FORM
    Publication number: 20220040917
    Abstract: The present invention is directed to a process for the preparation of a coated solid pharmaceutical dosage form using 3D printing technology.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 10, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Malte BOGDAHN, Stefan SCHILLER, Andrea HANEFELD, Simon GEISSLER